🇺🇸 FDA
Patent

US 10953209

Treating tumors using TTFields combined with a PARP inhibitor

granted A61KA61K31/502A61P

Quick answer

US patent 10953209 (Treating tumors using TTFields combined with a PARP inhibitor) held by The Board of Regents of the University of Texas System expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/502, A61P, A61P35/00